These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 23183529

  • 21. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
    Ben Yakov G, Montano D, Abu Freha N, Etzion O, Dizingof V, Mushkalo A, Shwarts D, Monitin S, Takchick A, Zilberman D, Sikuler E, Fich A.
    Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
    [Abstract] [Full Text] [Related]

  • 22. Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort.
    Mauss S, Böker K, Buggisch P, Christensen S, Hofmann WP, Schott E, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D.
    Z Gastroenterol; 2015 Jul; 53(7):644-54. PubMed ID: 26167694
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
    Calleja JL, Pascasio JM, Ruiz-Antorán B, Gea F, Bárcena R, Larrubia JR, Pérez-Álvarez R, Sousa JM, Romero-Gómez M, Solá R, de la Revilla J, Crespo J, Navarro JM, Arenas JI, Delgado M, Fernández-Rodríguez CM, Planas R, Buti M, Forns X, Spanish Group for the Study of the Use of Direct-Acting Drugs Hepatitis C with Severe Fibrosis.
    Liver Int; 2015 Jan; 35(1):90-100. PubMed ID: 25113158
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP, Markova AA, Calle Serrano B, Cornberg M.
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.
    Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, Marcellin P.
    Hepatology; 2010 Feb; 51(2):388-97. PubMed ID: 19918980
    [Abstract] [Full Text] [Related]

  • 30. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.
    Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM.
    Hepatology; 2012 Aug; 56(2):464-73. PubMed ID: 22334369
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure.
    Mandorfer M, Steiner S, Schwabl P, Payer BA, Aichelburg MC, Grabmeier-Pfistershammer K, Trauner M, Reiberger T, Peck-Radosavljevic M.
    Wien Klin Wochenschr; 2016 Jun; 128(11-12):414-20. PubMed ID: 26659706
    [Abstract] [Full Text] [Related]

  • 38. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
    Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P, Austrian Hepatitis Study Group.
    Gastroenterology; 2008 Aug; 135(2):451-8. PubMed ID: 18503773
    [Abstract] [Full Text] [Related]

  • 39. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF, El Dweik NZ, Al Kaabi SR, Al-Marri AD, Pasic F, Bener AB, Shebl FM, Amer AM, Butt MT, Yakoob R, John A, Al Mohanadi M, Al Khinji MA.
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [Abstract] [Full Text] [Related]

  • 40. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P, Yang JM, Hou W, Song SD, Wang L, Lu W.
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.